Literature DB >> 19122026

The need for biomarkers in amyotrophic lateral sclerosis drug development.

Kathryn R Wagner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19122026     DOI： 10.1212/01.wnl.0000338538.18938.9d

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  An improved electrical impedance myography (EIM) tongue array for use in clinical trials.

Authors:  Courtney McIlduff; Sung Yim; Adam Pacheck; Tom Geisbush; Aleksandar Mijailovic; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2015-07-02       Impact factor: 3.708

2.  Quantitative ultrasound of the tongue: Echo intensity is a potential biomarker of bulbar dysfunction in amyotrophic lateral sclerosis.

Authors:  C E McIlduff; M G Martucci; C Shin; K Qi; A K Pacheck; H Gutierrez; M Mortreux; S B Rutkove
Journal:  Clin Neurophysiol       Date:  2020-07-17       Impact factor: 3.708

3.  Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis.

Authors:  Meghan E Wilson; Imene Boumaza; David Lacomis; Robert Bowser
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

4.  Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically.

Authors:  Melinda Paizs; Massimo Tortarolo; Caterina Bendotti; József I Engelhardt; László Siklós
Journal:  Amyotroph Lateral Scler       Date:  2011-05-30

5.  Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis.

Authors:  Anu Mary Varghese; Aparna Sharma; Poojashree Mishra; Kalyan Vijayalakshmi; Hindalahalli Chandregowda Harsha; Talakad N Sathyaprabha; Srinivas Mm Bharath; Atchayaram Nalini; Phalguni Anand Alladi; Trichur R Raju
Journal:  Clin Proteomics       Date:  2013-12-02       Impact factor: 3.988
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.